Press Release - HBM Holdings

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release

Press Release In the News Image Library Awards & Recognitions

March 28, 2024

Harbour BioMed Reports Full Year 2023 Financial Results

Cambridge, MA, Rotterdam, NL, Suzhou, CN — March 28, 2024 Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharma...
View more
January 24, 2024

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.

Cambridge, MA, Rotterdam, NL, Suzhou, CN Harbour BioMed (the “Company”, HKEX: 02142) announced that the Company has been granted the c...
View more
January 19, 2024

Harbour BioMed Announces Positive Profit Alert

Cambridge, MA, Rotterdam, NL, Suzhou, CN – Jan 19, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical c...
View more
December 15, 2023

Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

Harbour BioMed's Wholly-owned Subsidiary, Nona Biosciences, announced today that it has entered into an exclusive license agreement with Pfizer Inc. for th...
View more
August 28, 2023

Harbour BioMed Announces 2023 Interim Results

Cambridge, MA, Rotterdam, NL, Suzhou, CN - August 28, 2023 Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global ...
View more
August 28, 2023

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

Cambridge, MA, Rotterdam, NL, Suzhou, CN— August 28, 2023 Harbour BioMed (the“Company”, HKEX: 02142) announced that the U.S. Foo...
View more
August 08, 2023

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

Cambridge, MA, Rotterdam, NL, Suzhou, CN – August 8, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical...
View more
July 13, 2023

Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation

Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 13, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more
June 29, 2023

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 29, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more
June 05, 2023

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour ...
View more